key: cord-0974050-2z701e6n
authors: Gorelik, Mark
title: Learning about Kawasaki disease from COVID-19 and the Multisystem Inflammatory Syndrome in Children
date: 2021-07-23
journal: Curr Opin Pediatr
DOI: 10.1097/mop.0000000000001047
sha: 454771ceb5c24024c670daa243425fb9f42b3a26
doc_id: 974050
cord_uid: 2z701e6n

PURPOSE OF REVIEW: Multisystem Inflammatory Syndrome in Children (MIS-C) is a novel syndrome that has appeared in the wake of the severe acute respiratory syndrome coronavirus -2 pandemic, with features that overlap with Kawasaki disease (KD). As a result, new interest and focus have arisen in KD, and specifically mechanisms of the disease. RECENT FINDINGS: A major question in the literature on the nature of MIS-C is if, and how, it may be related to KD. This has been explored using component analysis type studies, as well as other unsupervised analysis, as well as direct comparisons. At present, the answer to this question remains opaque, and several studies have interpreted their findings in opposing ways. Studies seem to suggest some relationship, but that MIS-C and KD are not the same syndrome. SUMMARY: Study of MIS-C strengthens the likelihood that KD is a postinfectious immune response, and that perhaps multiple infectious agents or viruses underlie the disease. MIS-C and KD, while not the same disease, could plausibly be sibling disorders that fall under a larger syndrome of postacute autoimmune febrile responses to infection, along with Kawasaki shock syndrome.

Multisystem Inflammatory Syndrome in Children (MIS-C) was first described as a 'Kawasaki like' illness in children, which occurred in a sudden spike of cases about 4 weeks after a major wave of severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) infection had passed through the general population [1] . Cases were initially described in multiple European centers, and following that in North America and internationally, and were then recognized as a distinct syndrome affecting children, temporally associated with SARS-CoV-2 infection [2] . Clinically, MIS-C is an acute febrile illness associated with either an apparent distributive shock, myocardial mechanical dysfunction, or both, as well as several cutaneous features including conjunctivitis, rash, and rash or edema of the distal extremities. The syndrome is also characterized as manifesting in some patients with peritonitis-like abdominal pain features and neurologic complications [2] . Although these presenting signs and symptoms appear nonspecific, MIS-C diagnosis recalls clinical features of Kawasaki disease (KD) when analyzed in comparison with febrile control patients [3] [4] [5] .

This clinical similarity of MIS-C to KD has inevitably led to questions regarding whether the disease is closely related to KD itself, presenting in this instance as a response to SARS-CoV-2 infection, or whether it represents an entirely separate syndrome [6, 7, 8 

MIS-C, unlike KD, has a very low incidence in east Asia. Although in some ways mirroring the SARS-CoV-2 global footprint, there were no reports of MIS-C during the first large wave in Wuhan, China, in which some 80,000 individuals were infected over a short period of time [9] . KD however has a distinctly higher incidence in east Asia as compared to Europe, North America or Africa [10, 11] . Moreover, KD in North America maintains a predilection in terms both of severity and likely frequency for individuals of East Asian heritage [12] . MIS-C, conversely, may have increased incidence in black and Hispanic populations [13 & ]. These differences in incidence between populations suggest a genetic risk factor may play a role in the pathogenesis of KD, and similarly, a genetic factor may play a role in MIS-C. For KD, several genetic variants, more commonly seen in east Asian populations, have been identified as potential genetic risk factors [14] . However, for MIS-C, as of the time of writing this review, no strong genetic factors have been identified, despite considerable effort of various groups to sequence many of these patients. (Very recent studies suggest a potential link to specific human leukocyte antigen (HLA)-1 subclasses [15 && ].) Despite this, it is almost assured that as with KD, multiple risk alleles underlie MIS-C. Study of MIS-C however is confounded by the very broad set of clinical criteria and lack of validated case definition. This difficulty in identifying the precise MIS-C phenotype is likely to blame for lack of success in finding risk alleles, as cohorts may contain patients with fever but other diagnoses.

KD has long been known to have incidence affected by seasonality, and also appears to erupt sporadically in large 'outbreaks' [16] . Intriguingly, not only does the disease itself have this periodicity, but in addition response to therapy also is affected by season of the year [17, 18] . If accepting the hypothesis that there is an underlying link between MIS-C and KD, all of this data together would suggest that KD itself is almost certainly induced by preceding viral infection, as opposed to other causes (such as a primary phenomenon or related to environmental factors [19] ) and that these are likely to be multiple different viruses each of which is associated with variations in presentation and response to therapy.

KD is well known to have an increased incidence in children between 6 months and 5-6 years of age [20] . This contrasts significantly with the median age and distribution of MIS-C cases, with a median age of about 9 years, and a lack of peak age incidence [13 & ]. This puzzle, at present without any solution, could when solved yield insights into the nature and etiology of KD. One potential consideration is that as they age, children are exposed and develop immunity to a number of viruses that could potentiate KD. By the time they reach preadolescence, they have effectively seen all of these viral agents. On the other hand, SARS-CoV-2 is a novel virus and therefore strikes all ages equally. Going forward, the natural history of SARS-CoV-2 (without a vaccine) could perhaps be primarily that of MIS-C in the younger age range (similar to KD) as opposed to an adult onset infectious syndrome.

Prior to any discussion of the clinical/laboratory features of MIS-C, it is important to stress that no single diagnostic criteria for MIS-C has been defined, and this is a significant problem, because data and descriptive findings may not be generalizable between institutions. Certain groups have included patients without any past evidence of SARS-CoV-2infection/serology in their patient groups with

&& ], and others, using the WHO or CDC guidelines, also include patients neither meeting KD criteria nor having any end cardiac or other organ injury, but only persistent fever (and some of these patients may overlap with patients who do not have SARS-CoV-2 serology positivity) [13 & ,21 & ]. This may result in a 'too broad' catchment of MIS-C patients, and raises potential concerns. In certain series, for instance, laboratory features/cytokine concentrations of patients without positive serology

MIS-C and KD appear to have clinical and laboratory features, as well as translational research findings, that suggest they are related conditions, but not the same disease.

Subtle clinical features, such as the presence of uveitis in KD and MIS-C, but not in TSS, further strengthen this likely association.

Epidemiologic differences between MIS-C and KD may indicate the presence of genetic risk factors in certain populations favoring one or the other presentation.

Lack of validated case definition for MIS-C may lead to lack of generalizability between studies especially in the translational arena. truly MIS-C, or rather contemporaneous febrile controls? Are patients without evidence of mechanical cardiac dysfunction and elevated markers of cardiac stress/damage (ntBNP or troponin) [23 && ] representative of MIS-C or another syndrome? This is important, because with no evidence of past SARS-CoV-2 infection and/or no evidence of end-organ dysfunction, management should be quite different. On the other hand, a reasonable counter-argument could be that there may be a rate of aneurysm development in 'MIS-C' patients not meeting KD criteria and not having acute end-organ damage that is being missed. In short, establishing a robust and validated MIS-C diagnostic criteria which captures true pathology is quite urgent. Once prevalence of SARS-CoV-2 declines, the positive predictive value of criteria with poor specificity will be very low.

Clinically, overlap between KD and MIS-C is such that a significant number of cases of MIS-C meet criteria for KD. In the largest report on these patients, a full 40% of these patients met criteria either for complete or incomplete KD [13 & ]. These features however may also overlap with toxic shock syndrome (TSS) [24] . This has raised whether in fact MIS-C is a toxic shock phenomenon, and may be driven by a superantigen like motif that appears to be present on the S protein [25] . Some small clues hint that rather, MIS-C is a sibling disorder of KD, and less likely a TSS, with caveats. KD ocular findings are associated with anterior uveitis -inflammation of the anterior and chambers of the eye in nearly 90% of patients [26] . The same type of anterior uveitis is also seen in MIS-C (and not described as a common feature in TSS), and in one case series, was seen in all patients with MIS-C who had a slit lamp examination [27 & ,28 ]. Findings such as abdominal pain (severe enough to warrant concern for appendicitis) and neurologic features which occur in a portion of patients with MIS-C, are also seen in severe KD and KD shock syndrome (KDSS; albeit also in TSS [24] ); in one series, several patients with KD had surgery for presumed appendicitis [29] [30] [31] [32] [33] . Unusual features of MIS-C, such as severe cervical lymphadenitis (authors observation) sometimes mistaken for bacterial lymphadenitis or retropharyngeal abscess, have also been described in large series of patients in KD [34] . In short -MIS-C appears to look like KD about 40% of the time, and other symptoms more frequently seen in MIS-C are well described as atypical features of KD. Although there may be some overlap in broad strokes with TSS, detailed consideration of symptoms suggest that a KD like pathophysiology is more likely. Despite this, the caveat is that superantigen mediated disease is complex: guttate psoriasis, a condition that is characterized by focal skin lesions, is augmented by a superantigen process [35] . Thus, it could also be conceivable that a mixed process -both specific antigen mediated immunity and a superantigen process, is at play. A summary of epidemiologic and clinical differences between KD and MIS-C is presented in Table 1 . 

Laboratory features of MIS-C have been areas in which differences between KD and MIS-C appear to be laid most bare, but yet at the same time these yield very important clues to these syndromes. In particular, lymphopenia and thrombocytopenia are quite characteristic of essentially all patients with MIS-C (authors observation and [13 & ]) and not described in typical KD [20] . Noteworthy here is the high similarity of laboratory features in one series to a comparator group with TSS [21 & ]. This lymphopenia and thrombocytopenia may be important clues to the etiology of disease, with platelet consumption suggesting a microthombotic process, whereas lymphocytes may be homing to end organs. In typical KD, the platelet counts are markedly elevated as an acute phase reactant. KDSS, described only in 2009 [36] , however, seems to have more closely approximately the findings in MIS-C, with patients in small series described to have lymphopenia and thrombocytopenia much more frequently than patients with KD [37] . KDSS, in the current paradigm of KD, is seen as a rare variation of an already relatively uncommon disease. In depth study of KDSS has not been possible due to its rarity. A recent more comprehensive review and comparison of KDSS and MIS-C shows several similarities, but yet still several differences [38] . Although KDSS is as frequently characterized by lymphopenia and thrombocytopenia than MIS-C, at the same time the degree of these changes are more pronounced in MIS-C, whereas the frequency of aneurysms is much less in MIS-C than in KDSS [38] . The authors conclude that MIS-C and KDSS are not the same entity, which appears to be a reasonable conclusion. What is perhaps also worth asking, based on this approach, is whether KD and KDSS are in fact the same entity -or whether perhaps they too are separate syndromes. Laboratory features are summarized in Table 2 .

A flurry of translational studies emerged in the months following the emergence of MIS-C, as many institutions and investigator groups sought to tackle the mission of etiology and mechanism of disease. Many of these studies have focused on immunologic phenotyping of cells in the peripheral circulation as a means of understanding the mechanisms of disease.

One of the first studies on this issue demonstrated activated T cells in the peripheral circulation, especially CD8þ non naïve T cells [39 && ]. These CD8þ T cells also expressed higher levels of CX3CR1, which is a vascular endothelium honing receptor [39 && ,40] . This finding would be consistent with a hypothesis, developing both from clinical observations and other studies, that injury to vascular endothelium, is a primary driver of the disease, and that CD8 T cells are a major player in pathophysiology. In support of this, elevated soluble C5b-9 was described in the plasma of patients with MIS-C, which is the activation product of the terminal complement cascade [41 & ]. Although CX3CR1 upregulation has not been described in KD, it is notable that it has been described in Henoch-Schonlein purpura and granulomatosis with polyangiitis [42, 43] . One would expect, as a vasculitis, this finding would likely be evident in KD as well, and perhaps speaks to the vascular inflammatory nature of MIS-C. A second cellular marker of interest was the finding of elevated CD64 on monocytes and neutrophils vs healthy controls which normalized during recovery [22 && ]. This finding has also been described in KD, when comparing CD64 expression on monocytes and neutrophils to KD patients after intravenous immunoglobulin therapy [44] .

In a more direct attempt to analyze the relationship between KD and MIS-C by the Brodin group (Stockholm), it was suggested that the hyperinflammatory state in MIS-C differed qualitatively from KD by principal component analysis of a large group of cytokines and chemokines from these patients [45 && ]. Perhaps most intriguingly, the same group found a particular auto-antibody to Endoglin in MIS-C patients, a glycoprotein expressed in the endothelium, with a subset of KD patients also expressing this auto-antibody. Plasma Endoglin was also elevated in MIS-C patients, suggesting that the presence of the antibody may not be causal, but rather an effect of vascular damage [45 && ]. A second group (Bogunovic, New York) performed a differential antibody analysis and found antibodies to anti-La, Anti-Jo-1, which are found in Lupus and Myositis syndromes, as well as a host of antibodies to inflammatory mediators, such as IL-6R. This group also found an IL-17 activation signal for MIS-C [46 && ], as did a third group of investigators [22 && ]. Another group described the finding of elevated CXCL-9 in patients with MIS-C [47], but did not perform comparisons to KD, whereas another group found CXCL-9 elevated in MIS-C vs KD [48] . Interferon gamma signal was also seen along with elevated GMcerebrospinal fluid in MIS-C vs KD patients in another investigation [49] . The apparently contradictory data among groups may be either due to differences in case definition, or perhaps, typical of early laboratory-based investigation in which challenging assays on variable samples requires time to bring out signal from noise. The likely consideration is that both of these factors are playing a role.

Binding of serum antibodies to cardiac endothelial cells in culture was described as well in a recent investigation, however, the authors note that this could be either causal or an effect of vascular damage [50 && ]. Finally, T cell receptor skewing either suggestive of superantigen [15 && ,51 & ], or perhaps a nonpeptide antigen [52] . This finding is potentially paradigm shifting, and may provide insights into the nature of both KD and MIS-C. Although superantigen as an etiology for KD was debated and finally discarded [53] , the question should perhaps be raised again, given the finding that increased skewing was seen with increased severity of MIS-C [15 && ]. With this, the question becomes whether T-cell skewing (if due to superantigen) was previously not consistently seen in KD because previous studies had variability in severity in their cohorts, and that it may be evident in KDSS. Having said this -the HLA-1 subclass association with MIS-C found by the same authors throws a wrench into the hypothesis, as it also requires a new process of superantigen/major histocompatibility complex (MHC) interaction, as these generally believed to be mediated via MHC-2, and not MHC-1 interactions [15 && ]. Intriguingly, HLA subclass associations with KD, when described, have also been HLA-1 [54, 55] . A non-comprehensive set of translational findings in KD vs MIS-C is described in Table 3. CONCLUSION MIS-C, since its emergence abruptly a mere 12-14 months ago, has captured the attention of the much of the medical and scientific community along with SARS-CoV-2 infection. With this, the clinical similarity to KD has also allowed Table 3 . Translational research findings in MIS-C and KD (all data is generally preliminary for MIS-C) investigation into KD an order of magnitude greater than the decades that preceded MIS-C. Clinically, both from an examination and laboratory point of view, and also from a translational research perspective, a relationship with KD seems almost too strong to dismiss. As a result of our experience with MIS-C, we now can say with much greater certainty -(1) that KD is an immunologic response to a preceding infection, likely viral; (2) that several viruses, and not a single virus, may induce this immunologic response; (3) that additional underlying genetic risk factors remain to be discovered for KD; (4) that activated CD8 T cells mediate the pathology of KD and perhaps (5) that KD itself is one of several diseases that would be classified together with MIS-C and KD shock as subtypes of a syndrome. These are all quite significant steps forward for a disease that, prior to 2020, was still regarded as a mystery in terms of etiology, mechanism and even classification within human disease.

Kawasaki-like disease: emerging complication during the COVID-19 pandemic

Multisystem inflammatory syndrome in children: an international survey

Discriminating multisystem inflammatory syndrome in children requiring treatment from common febrile conditions in outpatient settings

Distinguishing features of patients evaluated for multisystem inflammatory syndrome in children

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

Multisystem inflammatory syndrome in children and Kawasaki disease: two different illnesses with overlapping clinical features

SARS-CoV-2-related inflammatory multisystem syndrome in children: different or shared etiology and pathophysiology as Kawasaki disease?

childhood multisystem inflammatory syndrome -a new challenge in the pandemic

COVID-19 and Kawasaki disease in children

The global epidemiology of Kawasaki disease: Review and future perspectives

The epidemiology of Kawasaki disease: a global update

Hospitalizations for Kawasaki syndrome among children in the United States

Multisystem inflammatory syndrome in US Children and Adolescents

Largest US summary of patient characterisitcs and outcomes from 2020

Immunogenetics of Kawasaki disease

HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children

Seasonality and temporal clustering of Kawasaki syndrome

Seasonality of i.v. immunoglobulin responsiveness in Kawasaki disease

Seasonality in clinical courses of Kawasaki disease

On the interpretation of the atmospheric mechanism transporting the environmental trigger of Kawasaki Disease

Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

Large study and one of earliest large cohorts of MIS-C from the United Kingdom

Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection

Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children

Describes multiple patients from Boston with MIS-C and distinguishes from Kawasaki disease and macrophage activation syndrome

Toxic shock syndrome. Evidence of a broad clinical spectrum

COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): A novel disease that mimics toxic shock syndrome-the superantigen hypothesis

Anterior uveitis associated with Kawasaki syndrome

Bilateral acute anterior uveitis and corneal punctate epitheliopathy in children diagnosed with multisystem inflammatory syndrome secondary to COVID-19

COVID-19 related multi-inflammatory syndrome presenting with uveitis -a case report

Gastrointestinal presentation of Kawasaki disease: a red flag for severe disease?

Intestinal involvement in Kawasaki disease

Neurological complications in Kawasaki disease

Neurological complications of Kawasaki disease

Neurological involvement in Kawasaki disease: a retrospective study

Deep neck space involvement of Kawasaki disease in the US: a population-based study

Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis

Recognition of a Kawasaki disease shock syndrome

Describing Kawasaki shock syndrome: results from a retrospective study and literature review

Kawasaki disease shock syndrome in japan and comparison with multisystem inflammatory syndrome in children in European countries

Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19

Inflammatory function of CX3CR1þ CD8þ T cells in treated HIV infection is modulated by platelet interactions

Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2

Analsysis of MIS-C vs. acute COVID-19 infection, describes differences between these entities

Involvement of activated cytotoxic T lymphocytes and natural killer cells in Henoch-Schonlein purpura nephritis

Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosispossible role in vascular inflammation

Markedly elevated CD64 expression on neutrophils and monocytes as a biomarker for diagnosis and therapy assessment in Kawasaki disease

The immunology of multisystem inflammatory syndrome in children with COVID-19

Plasmacytoid dendritic cells depletion and elevation of IFN-gamma dependent chemokines CXCL9 and CXCL10 in children with multisystem inflammatory syndrome

Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study

Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease

Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children

Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation

First description of potential superantigenic character of spike protein and TCR skewing repertoire

A subset of human autoreactive CD1c-restricted T cells preferentially expresses TRBV4-1(þ) TCRs

Kawasaki syndrome: role of superantigens revisited

Polymorphisms of human leukocyte antigen genes in Korean children with Kawasaki disease

HLA-B Ã 54:01 is associated with susceptibility to Kawasaki disease

Financial support and sponsorship This work was supported by the National Institutes of Health, grant # K-08 HL155033, AAAAI Faculty Development Award.